MORRISVILLE, N.C., Sept. 12 /PRNewswire/ -- AVOS Life Sciences announced today that Richard Evans has joined AVOS as Vice President. His primary responsibility will be providing advisory services to companies in the prescription drug and biotech areas as well as selected investment assignments in capital markets. As an Institutional Investor (II) rated drug analyst, he will also have responsibility for AVOS' emerging portfolio of research products in the capital markets area.
"Richard brings us a senior level perspective on the drug industry," said Neil MacAllister, president of AVOS Life Sciences. "His background in capital markets complements our team and helps position AVOS as one of the strongest research and analysis firms in the pharmaceutical industry."
Mr. Evans has received several national awards from publications such as Bloomberg Markets magazine. He has been profiled in Barron's and Street.com. Richard has also provided financial commentary for The Wall Street Journal, The New York Times, CNBC, CNN, and NPR.
Mr. Evans earned a master's degree in Public and Private Management from Yale University. He is also a Doctor of Veterinary Medicine, having received his degree from North Carolina State University.
"One of AVOS' strengths," continued MacAllister, "is our first hand experience gained through extensive consulting engagements delivering strategic, operational and financial insight to healthcare and drug companies. Richard's expertise in analyzing financial market conditions will greatly add to AVOS' ability to deliver actionable recommendations to our clients by providing them with a full understanding of capital market reaction."
AVOS Life Sciences, LLC is a healthcare consulting and research firm
located in Morrisville, North Carolina, and New York, New York. The company
helps clients understand the rapidly evolving pharmaceutical,
biotechnology, medical device and diagnostic market segments, thereby
|SOURCE AVOS Life Sciences, LLC|
Copyright©2007 PR Newswire.
All rights reserved